Experience

BioAgilytix

• United States
• Biotechnology Research
• 700 & Above Employee

• Senior Director, DMPK

  • Aug 2021 - Present

  San Diego, California, United States

• Senior Director, DMPK

  • Aug 2015 - Present

  Greater San Diego Area

• Director, DMPK

  • Aug 2000 - Aug 2015

  I am responsible for the design and oversight of the in vitro drug metabolism experiments needed during the discovery and clinical phases of the drug development process. My expertise covers a wide range of research including metabolic stability, CYP450 inhibition and induction, metabolite profiling and identification, and reaction phenotyping. Additionally, I oversee non-GLP bioanalytical research in support of pharmacokinetic, toxicokinetic, and protein binding studies.



Pharmazyme

• Drug Metabolism Product Development Manager

  • Mar 1999 - Aug 2000

  Conceived, designed, and developed an in vitro drug metabolism contract research program utilizing recombinant cytochrome P450s and other drug metabolizing enzymes that were cloned by Dr. Henry Barnes. The program included the marketing and selling of the enzyme products and the use of these products in contract assay services. Wrote and obtained a Phase I SBIR NIH grant ($100,000) in conjunction with Dr. Henry Barnes to do research on the use of these enzymes for large-scale fine chemical… Show more Conceived, designed, and developed an in vitro drug metabolism contract research program utilizing recombinant cytochrome P450s and other drug metabolizing enzymes that were cloned by Dr. Henry Barnes. The program included the marketing and selling of the enzyme products and the use of these products in contract assay services. Wrote and obtained a Phase I SBIR NIH grant ($100,000) in conjunction with Dr. Henry Barnes to do research on the use of these enzymes for large-scale fine chemical synthesis. Show less



Hybritech

• Research Assistant

  • Feb 1992 - Aug 1993

  Primary team member who designed, developed, and implemented a computerized robotic system for radiolabeling monoclonal antibodies for use in medical diagnostic kits. Wrote and established Standard Operating Procedures and validation protocols for using the above system in compliance with FDA Good Manufacturing Practices.